Health
Regeneron halts trial of antibody treatment in seriously ill Covid patients – Financial Times
Drug hailed as coronavirus ‘cure’ by Donald Trump will still be studied in mild-to-moderate cases
Regeneron has stopped enrolling seriously ill Covid-19 patients in a clinical trial of the antibody treatment that US President Donald Trump has hailed as a “cure” for the disease.
Shares in Regeneron fell as much as 3 per cent after an independent data monitoring committee warned that the risks might outweigh the benefits for hospitalised patients on high levels of oxygen.
The move comes after Eli Lilly, which is also developing a Covid-19 antibody treatment, stopped its trial in hospitalised…
-
General24 hours agoTens of thousands protest in nationwide action against war in Gaza
-
General21 hours agoThousands flood cities demanding action on Palestine
-
General23 hours agoAuthorities say charged man used false name to escape from Perth court
-
Noosa News23 hours agoSkybound Gymnastics owner and coach Wei Jun Lee charged with sexual assault of teenager